There's Reason For Concern Over Abbisko Cayman Limited's (HKG:2256) Massive 29% Price Jump

Simply Wall St · 3d ago

Abbisko Cayman Limited (HKG:2256) shares have continued their recent momentum with a 29% gain in the last month alone. The last month tops off a massive increase of 127% in the last year.

Although its price has surged higher, there still wouldn't be many who think Abbisko Cayman's price-to-sales (or "P/S") ratio of 9x is worth a mention when the median P/S in Hong Kong's Biotechs industry is similar at about 10x. However, investors might be overlooking a clear opportunity or potential setback if there is no rational basis for the P/S.

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

Check out our latest analysis for Abbisko Cayman

ps-multiple-vs-industry
SEHK:2256 Price to Sales Ratio vs Industry May 9th 2025

How Has Abbisko Cayman Performed Recently?

Abbisko Cayman certainly has been doing a good job lately as it's been growing revenue more than most other companies. Perhaps the market is expecting this level of performance to taper off, keeping the P/S from soaring. If you like the company, you'd be hoping this isn't the case so that you could potentially pick up some stock while it's not quite in favour.

Keen to find out how analysts think Abbisko Cayman's future stacks up against the industry? In that case, our free report is a great place to start.

Do Revenue Forecasts Match The P/S Ratio?

There's an inherent assumption that a company should be matching the industry for P/S ratios like Abbisko Cayman's to be considered reasonable.

Retrospectively, the last year delivered an explosive gain to the company's top line. Spectacularly, three year revenue growth has also set the world alight, thanks to the last 12 months of incredible growth. Therefore, it's fair to say the revenue growth recently has been superb for the company.

Shifting to the future, estimates from the seven analysts covering the company suggest revenue growth is heading into negative territory, declining 0.5% per year over the next three years. That's not great when the rest of the industry is expected to grow by 51% each year.

In light of this, it's somewhat alarming that Abbisko Cayman's P/S sits in line with the majority of other companies. It seems most investors are hoping for a turnaround in the company's business prospects, but the analyst cohort is not so confident this will happen. There's a good chance these shareholders are setting themselves up for future disappointment if the P/S falls to levels more in line with the negative growth outlook.

The Key Takeaway

Its shares have lifted substantially and now Abbisko Cayman's P/S is back within range of the industry median. Using the price-to-sales ratio alone to determine if you should sell your stock isn't sensible, however it can be a practical guide to the company's future prospects.

While Abbisko Cayman's P/S isn't anything out of the ordinary for companies in the industry, we didn't expect it given forecasts of revenue decline. With this in mind, we don't feel the current P/S is justified as declining revenues are unlikely to support a more positive sentiment for long. If the poor revenue outlook tells us one thing, it's that these current price levels could be unsustainable.

It's always necessary to consider the ever-present spectre of investment risk. We've identified 2 warning signs with Abbisko Cayman (at least 1 which makes us a bit uncomfortable), and understanding them should be part of your investment process.

If companies with solid past earnings growth is up your alley, you may wish to see this free collection of other companies with strong earnings growth and low P/E ratios.